Hartmut Döhner

Hartmut Döhner is one of the world's foremost authorities on the molecular genetics of acute myeloid leukemia (AML). As Professor and Chairman of Internal Medicine III at the University of Ulm, he has spent more than three decades systematically mapping the genomic landscape of AML, translating those discoveries into risk-stratification frameworks that are now embedded in international treatment guidelines. His group was among the first to establish the prognostic significance of cytogenetic and molecular aberrations—including NPM1 mutations, FLT3-ITD, and DNMT3A mutations—providing the clinical community with tools to stratify patients into distinct risk categories and select therapy accordingly. Döhner played a central role in drafting the European LeukemiaNet (ELN) AML recommendations, a consensus document that has been revised and expanded in 2010, 2017, and 2022 to incorporate new genomic insights. These guidelines are used globally to standardize diagnosis, risk stratification, and treatment selection for AML patients. He has led numerous landmark phase II and III trials evaluating novel targeted agents—most notably FLT3 inhibitors such as midostaurin and quizartinib—and has championed the integration of measurable residual disease (MRD) monitoring as a surrogate endpoint for survival outcomes. Beyond his laboratory and clinical work, Döhner is a prolific educator and mentor who has trained generations of hematologists at Ulm and through international collaborations. He has authored more than 500 peer-reviewed publications and book chapters, and his h-index reflects an outsized influence on how the field understands and treats the most common form of acute leukemia in adults. His continued leadership in multi-center cooperative groups across Europe and North America ensures that cutting-edge trial data reaches clinical practice rapidly.